Clinical Trial Update: A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating Aipalolitovorelizumab (QL1706) plus Fruquintinib for immunodominant pMMR/MSS metastatic colorectal cancer after second-line o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Aipalolitovorelizumab
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Harbin Medical University | Conditions: Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING